Vivus cuts U.S. deal for erectile dysfunction drug

An erectile dysfunction drug from Vivus Inc. — approved 1-1/2 years ago but never sold in the United States — will land the Mountain View-based company a $30 million upfront payment from a licensing deal with Auxilium Pharmaceuticals Inc...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.